Explore the words cloud of the CardioReGenix project. It provides you a very rough idea of what is the project "CardioReGenix" about.
The following table provides information about the project.
VRIJE UNIVERSITEIT BRUSSEL
|Coordinator Country||Belgium [BE]|
|Total cost||14˙839˙773 €|
|EC max contribution||14˙839˙773 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2019-01-01 to 2023-12-31|
Take a look of project's partnership.
|1||VRIJE UNIVERSITEIT BRUSSEL||BE (BRUSSEL)||coordinator||1˙987˙859.00|
|2||FINVECTOR OY||FI (KUOPIO)||participant||1˙601˙405.00|
|3||ITA-SUOMEN YLIOPISTO||FI (KUOPIO)||participant||1˙564˙156.00|
|4||CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL||DE (KIEL)||participant||1˙411˙526.00|
|5||THE UNIVERSITY OF EDINBURGH||UK (EDINBURGH)||participant||1˙356˙501.00|
|6||MEDIZINISCHE HOCHSCHULE HANNOVER||DE (HANNOVER)||participant||1˙193˙622.00|
|7||STICHTING VUMC||NL (AMSTERDAM)||participant||1˙106˙750.00|
|8||KING'S COLLEGE LONDON||UK (LONDON)||participant||1˙013˙675.00|
|9||CARDIOR PHARMACEUTICALS GMBH||DE (HANNOVER)||participant||908˙249.00|
|10||POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA||FI (KYS)||participant||890˙640.00|
|11||BATAVIA BIOSCIENCES BV||NL (LEIDEN)||participant||776˙507.00|
|12||A2F ASSOCIATES LIMITED||UK (NEWMARKET)||participant||718˙845.00|
|13||ASPHALION SL||ES (BARCELONA)||participant||310˙035.00|
WHO estimates 17.7 million people die each year from cardiovascular disease (CVD), an estimated 31% of all deaths worldwide. While progress with conventional treatments is making incremental gains, there remains a need to develop innovative therapeutic approaches. Gene therapy has gained significant momentum, mainly for treatment of rare monogenetic diseases. Marketing authorization for gene therapy products has not impacted diseases such as CVD. Recent, deeper understanding of the molecular/cellular mechanisms of CVD and technology associated with more efficient and safer gene therapy vectors has allowed new opportunities for development of next-generation ATMPs for CVD. CardioReGenix focuses on technological innovations for the treatment of CVD, in particular heart failure and myocardial ischemia. We aim to overcome bottlenecks in gene therapy for CVD by (i) maximizing cardiac-specific gene expression; (ii) maximizing cardiac-specific gene delivery; (iii) reducing adverse immune responses; (iv) optimizing manufacturing for research and clinical-grade ATMPs ; (v) validate new promising targets using in vitro and preclinical models; (vi) undertaking first-in-man studies; (vii) developing and implementing an exploitation and valorization strategy with strong EU SME involvement. CardioReGenix is a high risk/high gain project supported by robust preliminary data and multi-disciplinary consortium harnessing know-how in vector development, GMP manufacturing, preclinical and clinical cardiology, regulation of ATMP and liaising with EMA, business development and clinical translation. CardioReGenix will (i) strengthen Europe's competitive position in gene therapy development for CVD; (ii) improve the prospect of successfully treating patients suffering from CVD by gene therapy and (iii) develop and refine the latest gene therapy platforms that go significantly beyond the state of the art.
|year||authors and title||journal||last update|
Dongchao Lu, Thomas Thum
RNA-based diagnostic and therapeutic strategies for cardiovascular disease
published pages: , ISSN: 1759-5002, DOI: 10.1038/s41569-019-0218-x
|Nature Reviews Cardiology||2019-08-05|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDIOREGENIX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CARDIOREGENIX" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More